{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:10:58Z","timestamp":1793722258841,"version":"4.6.1"},"reference-count":21,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2020A1515010133"],"award-info":[{"award-number":["2020A1515010133"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sun Yat-sen University Clinical Research 5010 Program","award":["No. 2019006"],"award-info":[{"award-number":["No. 2019006"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. U20A20399 and 81870704"],"award-info":[{"award-number":["No. U20A20399 and 81870704"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Key-area Research and Development Program of Guangdong Province","award":["No.2020B0101130015"],"award-info":[{"award-number":["No.2020B0101130015"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation Grant","doi-asserted-by":"crossref","award":["2019M653207"],"award-info":[{"award-number":["2019M653207"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,8,3]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of omalizumab for chronic rhinosinusitis with nasal polyps (CRSwNP) and to identify evidence gaps that will guide future research on omalizumab for CRSwNP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>A comprehensive search was performed in PubMed, Embase, Web of Science and the Cochrane Library on 13 October 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>Randomised controlled trials (RCTs) comparing omalizumab with placebo, given for at least 16 weeks in adult patients with CRSwNP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>\n                      Two independent authors screened search results, extracted data and assessed studies using the Cochrane risk of bias tool. Data were pooled using the inverse-variance method and expressed as mean differences (MDs) with 95% CIs. Heterogeneity was assessed by the \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      test and the I\n                      <jats:sup>2<\/jats:sup>\n                      statistic.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of four RCTs involving 303 participants were identified. When comparing omalizumab to placebo, there was a significant difference in Nasal Polyps Score (MD=\u22121.20; 95% CI \u22121.48 to \u22120.92), Nasal Congestion Score (MD=\u22120.67; 95% CI \u22120.86 to \u22120.48), Sino-Nasal Outcome Test-22 (MD=\u221215.62; 95% CI \u221219.79 to \u221211.45), Total Nasal Symptom Score (MD=\u22121.84; 95% CI \u22122.43 to \u22121.25) and reduced need for surgery (risk ratio (RR)=5.61; 95% CI 1.99 to 15.81). Furthermore, there was no difference in the risk of serious adverse events ((RR=1.40; 95% CI 0.29 to 6.80), adverse events (RR=0.83; 95% CI 0.60 to 1.15) and rescue systemic corticosteroid (RR=0.52; 95% CI 0.17 to 1.61).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This was the first meta-analysis that identified omalizumab significantly improved endoscopic, clinical and patient-reported outcomes in adults with moderate to severe CRSwNP and it was safe and well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42020207639.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-047344","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T12:26:02Z","timestamp":1630671962000},"page":"e047344","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct01066104","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01066104","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01066104","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Qingwu","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China"},{"name":"Department of Allergy, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianxiong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Science and Research, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuekun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China"},{"name":"Department of Allergy, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3377-737X","authenticated-orcid":false,"given":"Qintai","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology-Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China"},{"name":"Department of Allergy, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"2025121511464575000_11.9.e047344.1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin20.600"},{"key":"2025121511464575000_11.9.e047344.2","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaip.2018.10.014","article-title":"Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting","volume":"7","author":"Benjamin","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025121511464575000_11.9.e047344.3","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2015.10.010","article-title":"Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis","volume":"136","author":"Bachert","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2025121511464575000_11.9.e047344.4","first-page":"343","article-title":"The Galen rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life","volume":"57","author":"Khan","year":"2019","journal-title":"Rhinology"},{"key":"2025121511464575000_11.9.e047344.5","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-017-0690-5"},{"key":"2025121511464575000_11.9.e047344.6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","article-title":"Chronic rhinosinusitis with nasal polyps","volume":"4","author":"Stevens","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025121511464575000_11.9.e047344.7","doi-asserted-by":"publisher","DOI":"10.1111\/all.12644"},{"key":"2025121511464575000_11.9.e047344.8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope"},{"key":"2025121511464575000_11.9.e047344.9","doi-asserted-by":"crossref","DOI":"10.1186\/s13601-019-0269-4","article-title":"Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis","volume":"9","author":"Calus","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"2025121511464575000_11.9.e047344.10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"key":"2025121511464575000_11.9.e047344.11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2025121511464575000_11.9.e047344.12","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-015-0157-5","article-title":"Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review","volume":"4","author":"Hong","year":"2015","journal-title":"Syst Rev"},{"key":"2025121511464575000_11.9.e047344.13","first-page":"CD013513","article-title":"Biologics for chronic rhinosinusitis","volume":"2","author":"Chong","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121511464575000_11.9.e047344.14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2025121511464575000_11.9.e047344.15","unstructured":"Wu Q , Zheng R , Qiu H . Anti-IgE monoclonal antibody in the treatment of chronic rhinosinusitis with nasal polyps. Prospero 2020 CRD42020207639. Available: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020207639"},{"key":"2025121511464575000_11.9.e047344.16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"2025121511464575000_11.9.e047344.17","unstructured":"Higgins JPT , Green S , eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. www.cochrane-handbook.org"},{"key":"2025121511464575000_11.9.e047344.18","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/alr.22028","article-title":"Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis","volume":"7","author":"Chowdhury","year":"2017","journal-title":"Int Forum Allergy Rhinol"},{"key":"2025121511464575000_11.9.e047344.19","unstructured":"NCT01066104. subcutaneous omalizumab for treatment of chronic rhinosinusitis with nasal polyposis, 2009. Available: https:\/\/ clinicaltrials.gov\/show\/nct01066104"},{"key":"2025121511464575000_11.9.e047344.20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/alr.22064","article-title":"Asthma onset pattern and patient outcomes in a chronic rhinosinusitis population","volume":"8","author":"John Staniorski","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"key":"2025121511464575000_11.9.e047344.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-4486.2009.01995.x"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-047344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:46:56Z","timestamp":1765828016000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-047344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,3]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/bmjopen-2020-047344"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-047344","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}